Pyxis Oncology
http://www.pyxisoncology.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pyxis Oncology
ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer
In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.
Finance Watch: Though Flush With Cash, Theseus Seeks Alternatives, Gets Two Quick Offers
Restructuring Edition: OrbiMed/Foresite and Concentra responded quickly after Theseus implemented a 72% workforce reduction and began a search for strategic alternatives despite having $225.4m in cash. REGENXBIO, Novavax and Lyell also revealed job cuts despite large cash stockpiles.
Funding Clicks Into Place For Tagworks
Backed by an international syndicate of investors including Novartis and Ysios Capital, Tagworks has raised a healthy sum to advance its proprietary click-to-release platform technology and take its first click-cleavable antibody-drug conjugate into the clinic.
Deal Watch: Gurnet Point, Novo Holdings Buy Out Paratek
Struggling antibiotic company will go privare under the agreement. Bayer will employ Acuitas's liquid nanoparticle technology in gene therapies developed by subsidiary Asklepios.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice